Bioorganic & Medicinal Chemistry 2018-04-04

Structure-Based Design and Synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino Derivatives as Janus Kinase 3 Inhibitors

Yuan Yin, Cheng-Juan Chen, Ru-Nan Yu, Zhi-Jian Wang, Tian-Tai Zhang, Da-Yong Zhang

Index: 10.1016/j.bmc.2018.04.005

Full Text: HTML

Abstract

Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. Here we report the discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidin-4-amino as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Our optimization study gave compound 12a, which exhibited potent JAK3 inhibitory activity (IC50 of 6.2 nM) as well as excellent JAK kinase selectivity (>60 fold). In cellular assay, 12a exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation (IC50 of 9.4 μM). Further, Compound 12a showed efficacy in delayed hypersensitivity assay. The data supports the further investigation of these compounds as novel JAKs inhibitors.

Latest Articles:

Development of concise two-step catalytic approach towards lasofoxifene precursor nafoxidine

2018-04-10

[10.1016/j.bmc.2018.04.021]

Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer’s disease

2018-04-09

[10.1016/j.bmc.2018.04.019]

Rational Design and Screening of Peptide-Based Inhibitors of Heat Shock Factor 1 (HSF1)

2018-04-07

[10.1016/j.bmc.2018.04.018]

Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells

2018-04-06

[10.1016/j.bmc.2018.04.016]

Screening of ligands for redox-active europium using magnetic resonance imaging

2018-04-04

[10.1016/j.bmc.2018.04.001]

More Articles...